ArticleBMC infectious diseases2012

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

Stefano Rusconi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.